Tasso Surpasses 1.5 Million Devices Sold: A Look Back at Recent Milestones
2024 was a landmark year for Tasso as we advanced our mission to make diagnostic testing more accessible and enhance the patient experience. With over 1.5 million devices sold, our innovative, patient-centric blood collection technology continues to transform the healthcare industry.
As we move further into 2025, Tasso remains at the forefront of the shift toward better patient experiences, reinforcing our commitment to deliver accessible diagnostics that empower clinicians and patients to make informed decisions.
To our partners and employees — whether in commercial, community, or clinical settings — we deeply value your collaboration. Together, we are driving innovation, improving patient care, and reaching new heights.
With this milestone as a backdrop, now is the perfect time to reflect on some of Tasso’s recent achievements.
Driving Innovation in Blood Collection Technology
Tasso introduced its next-generation dried blood spot (DBS) sample collection technology, a major step forward in sampling for clinical trials and sports anti-doping testing. The novel collection system combines Tasso’s newly announced Tile™-T20 dried whole blood cartridge with a Tasso™ Mini device, enabling the precise, convenient collection of DBS samples. By prioritizing ease of use and reliability alongside technological advances, we continue to redefine the patient experience in blood collection.
Shedding Light on Patient Experience and Access Challenges in Healthcare
A Tasso-commissioned survey revealed that one in three patients delay diagnostic blood testing due to anxiety, pain, and inconvenience — barriers that can lead to missed routine care and delayed diagnoses. Our work continues to focus on solving these challenges by providing an accessible, virtually painless alternative that fits patient lifestyles.
Forging Strategic Partnerships for Broader Impact
Tasso announced its partnership with ARUP Laboratories to enhance and accelerate decentralized clinical research. This collaboration combines our virtually painless, convenient blood collection technology with ARUP’s leading biomarker testing capabilities for a superior end-to-end testing option. By integrating our capabilities, clinical researchers now have a streamlined solution to collect high-quality samples remotely while maintaining gold standard test accuracy and reliability.
Strengthening Security and Compliance
Tasso successfully renewed its SOC 2 Type II compliance certification, reinforcing our commitment to the highest standards of data security and privacy. As remote blood collection becomes an integral part of clinical trials and decentralized healthcare, maintaining trust and regulatory compliance remains a top priority.